Management of HCV G4 Kasr Alainy

More documents

Recommendations

Info

Pariteprevir-ritonavir-Ombitasvir Agate II: Liver Tests Waked et al. AASLD 2016
Pariteprevir-ritonavir-Ombitasvir SVR12 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 100% France ANRS HEPATHER n=54 96.20% 96% Spain Real Life n=122 Saudi Arabia Real Life n=117 Fontaine H. et al. AASLD 2016, Crespo J et al, AASLD 2016, Alswat K, et al. AASLD 2016
Page 2 and 3: Management of Patients with HCV Gen
Page 4 and 5: SVR12 (%) Sofosbuvir-RBV • 2 stud
Page 6 and 7: SVR12, % Sofosbuvir-Ledipasvir N=35
Page 8 and 9: SOF-RBV, SOF-LED, SOF-VEL • Integ
Page 10 and 11: SVR12 % Grazoprevir-Elbasvir EBR +
Page 12 and 13: SVR-12 % Sofosbuvir-Simeprevir •
Page 14 and 15: Pariteprevir-ritonavir-Ombitasvir A
Page 18 and 19: Gelcaprevir-Pibrentasvir (GP) Surve
Page 20 and 21: SVR 12 (%) Outcome of DAA Treatment
Page 22 and 23: http://www.hcvguidelines.org, acces
Page 24 and 25: EASL Recommendations 2016 Retreatme
Page 26 and 27: Conclusion • Treatment of HCV G4

Management of HCV G4 Kasr Alainy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?